title: A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib.
abstract: Conjunctival malignant melanoma (CMM) is a rare malignancy and in the advanced setting there is no effective treatment. In contrast, half of cutaneous melanomas have BRAF mutations and treatment with BRAF inhibitors is established for patients with disseminated disease. The most common form of ocular melanoma, uveal melanoma, lacks these mutations, however, their presence has been reported for CMM.
  
  
  
  We used the BRAF inhibitor vemurafenib to treat a 53 year-old female suffering from a BRAF(V600E) mutated metastatic CMM. The patient benefited from the treatment, a response was evident within a week and she experienced a progression free survival of four months.
  
  
  
  To our knowledge, this is the first described case of response to vemurafenib treatment in a patient with ocular melanoma.
authors: Department of Oncology, Uppsala University Hospital, 751 85, Uppsala, Sweden.|Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
authors: A
authors: A
authors: Maleka
authors: Department of Oncology, Uppsala University Hospital, 751 85, Uppsala, Sweden.|Department of Surgery, Section of Radiology, Uppsala University, Uppsala, Sweden.
authors: G
authors: G
authors: Åström
authors: Novartis Sverige AB, Kemistvägen 1, 183 79, Täby, Sweden.
authors: P
authors: P
authors: Byström
authors: Department of Oncology, Uppsala University Hospital, 751 85, Uppsala, Sweden. Gustav.Ullenhag@igp.uu.se.|Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. Gustav.Ullenhag@igp.uu.se.
authors: G J
authors: GJ
authors: Ullenhag
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage* / Q000627:therapeutic use; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics; D008875:Middle Aged; D009154:Mutation; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors / Q000235:genetics*; D013449:Sulfonamides / Q000008:administration & dosage* / Q000627:therapeutic use; D016896:Treatment Outcome; D014604:Uveal Neoplasms / Q000188:drug therapy* / Q000235:genetics; D000077484:Vemurafenib; D000098943:Uveal Melanoma
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf
keywords: BRAF inhibitor; BRAF mutation; Conjunctival malignant melanoma; Ocular melanoma; Vemurafenib